- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Meningococcal Vaccine Menveo Gets Expanded Age Indication
New labeling includes infants and toddlers from 2 months of age (August 1)
The FDA has approved Menveo (Novartis), a meningococcal group A, C, W-135, and Y conjugate vaccine, for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis in infants and toddlers from 2 months of age. This expanded indication allows pediatricians to use a single vaccine to protect infants, children, and adolescents against four of the five most common serogroups that cause meningococcal disease.
Infants younger than 7 months old are the age group that is most vulnerable to meningococcal disease in the U.S. During their first year of life, infants are more than seven times more likely to contract the disease than 14- to 24-year-olds. Of the infants who contract the disease, more than 10% will die from it, and of those who do survive, approximately one in every five will suffer permanent side effects, including amputations, hearing loss, paralysis, and brain damage.
Menveo is a quadrivalent conjugate vaccine for use against invasive disease caused by four groups of the bacterium Neisseria meningitidis (A, C, Y, and W-135). The vaccine has been available for use in adolescents and adults aged 11 to 55 years since February 2010 and in children aged 2 to 10 years since January 2011.
Source: Novartis; August 1, 2013.